Clinical Trial Update: A Study to Assess the Safety, Tolerability, and Immunogenicity of RSVpreF in Older Adults in Korea [Phase 3]

View source ↗

Summary

Pfizer completed a Phase 3 trial in Korea evaluating the safety, tolerability, and immunogenicity of the RSVpreF vaccine in older adults. Results were posted on…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• RSVpreF

Snippet

Sponsor: Pfizer | Conditions: Respiratory Syncytial Virus | Phase 3 | Status: COMPLETED | Results posted: 2026-02-09